Potential therapeutic effects related to Covid-19

Clinical trials are recommended for products which are Interleukin-1 Inhibitors or Tyrosine Kinase Inhibitors

Research shows that nerolidol inhibits Interleukin-1β in vitro and in vivo:

  • Nerolidol inhibits the LOX-1 / IL-1β signaling

https://pubmed.ncbi.nlm.nih.gov/31926445/
"The administration of nerolidol reduced the severity of fungal keratitis with infiltration of fewer inflammatory cells and reduced levels of the LOX-1, as well the anti-inflammatory cytokines such as IL-1β"

"Nerolidol notably inhibited the increase of TNFα and IL-1β"

 

  • Nerolidol exhibits antinociceptive and anti-inflammatory activity: involvement of the GABAergic system and proinflammatory cytokines

https://pubmed.ncbi.nlm.nih.gov/26791997/
"Nerolidol reduced production of interleukin 1 beta (IL-1β) in LPS-stimulated, peritoneal macrophages."

 

  • Effect of nerolidol on cyclophosphamide-induced bone marrow and hematologic toxicity in Swiss albino mice

https://pubmed.ncbi.nlm.nih.gov/31987924/
"biochemical analysis revealed increased malondialdehyde (MDA), tumor necrosis factor α (TNF-α), interleukin (IL)-6, and IL-1β levels and reduced superoxide dismutase (SOD), catalase (CAT), and IL-10 levels (from cyclophosphamide).  Treatment with NER significantly reversed the hematotoxic and myelotoxic aberrations ( and retained the structural integrity of bone marrow."
 

Computer models indicate nerolidol has very good potential to inhibit Tyrosine Kinase:

  • Tyrosinase inhibitory activity, molecular docking studies and antioxidant potential of chemotypes of Lippia origanoides (Verbenaceae) essential oils

https://pubmed.ncbi.nlm.nih.gov/28459864/
"The best docking energies were observed with thymol and (E)-nerolidol (-79.8 kcal.mol-1), which suggested H-bonding interactions with Met281 and His263 (thymol) and His259, His263 ((E)-nerolidol)."

 

Devil's club essential oil (branch bark) contains more than 50% nerolidol and based upon published studies and CDC treatment guidelines is eligible to be a candidate for clinical trials for treatment of Covid-19.

IMG_0909_edited.jpg

Additional studies:

  • Suppresses inflammation during lung injuries

Nerolidol Suppresses the Inflammatory Response during Lipopolysaccharide-Induced Acute Lung Injury via the Modulation of Antioxidant Enzymes and the AMPK/Nrf-2/HO-1 Pathway  

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885193/

  • Antiviral agents in essential oils to treat SARS-CoV-2 (computer projection)

Essential Oils as Antiviral Agents. Potential of Essential Oils to Treat SARS-CoV-2 Infection: An In-Silico Investigation

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279430/

  • Computer molecular docking projection shows the strong potential of nerolidol for inhibiting viral replication and infection

COVID‑19 and therapy with essential oils having antiviral,
anti‑inflammatory, and immunomodulatory properties

https://pubmed.ncbi.nlm.nih.gov/32803479/

IMG_0909_edited.jpg

 

Devil's club essential oil (branch bark) has the potential to treat or pretreat for conditions caused by vaccine injury

Vaccine injuries reported announced by the CDC

https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html

and

VAERS database https://vaers.hhs.gov/data.html

Injury: Myocarditis/heart related (55k+)

Preventive effect of nerolidol on isoproterenol induced myocardial damage in Wistar rats: Evidences from biochemical and histopathological studies

https://pubmed.ncbi.nlm.nih.gov/31313346/

"Pretreatment with NRD at different doses (100 and 200 mg/kg b.w) for 21 days prevented the above changes induced by ISO. The 200 mg/kg b.w of NRD was more pronounced than the other dose and brought back all the above parameters near to normalcy."

No medical claims or recommendations are being made here.  This is merely a summary of the data published on government websites as it relates to the devil's club EO primary component nerolidol and potential treatments - and the repeating of requests by numerous researchers for clinical trials.